suPAR in clinical routine at Hospital General Universitario Santa Lucía
Fri Jun 26 2020
By: Julio Ajenjo García, ViroGates
Hospital General Universitario Santa Lucía is located in the city of Cartagena in the Murcia Region on the Spanish Mediterranean coast. It is a 667-bed hospital which serves as a reference hospital in this region with an uptake of approx. 300,000 people.
On June 23, the hospital decided to incorporate suPAR into its portfolio of services. The biomarker will be used to risk stratify patients treated in the Emergency Department for acute pathologies including patients suspected for having a COVID-19 infection.
suPAR is measured on the Core Labs’ cobas c501 system from Roche Diagnostics.
All work related to the technical and clinical implementation of suPAR at Hospital General Universitario Santa Lucía has been directed by Head of the Clinical Analysis Service Dra. María Dolores Albaladejo Otón and Dr. Luis García de Guadiana Romualdo, specialist in the Clinical Analysis Area.
Hospital General Universitario Santa Lucía is the second Spanish hospital in the last three months to add suPAR to its clinical routine program.
“We are very happy to have this new biomarker that has proven to be a useful tool in the ED for making decisions about the need for hospital admission or discharge. We hope that the first results demonstrating its usefulness in patients with
COVID-19 can be confirmed soon in our hospital.”
Dra. María Dolores Albaladejo Otón,
Head of the Clinical Analysis, Hospital General Universitario Santa Lucía, Spain
suPAR News Vol. 3, June 2020
